Study finds large numbers of students abuse prescription drugs to cope with stress of finals
WASHINGTON — Finals can be a stressful time for any college or graduate student, with many hours spent studying and few spent socializing or relaxing. But many students are using prescription drugs to get through finals, according to a new study.
the 621-person study, commissioned by the Digital Citizens Alliance and conducted by Zogby Analytics, found that one-in-three students reported taking prescription drugs to get through finals. The study included two online surveys conducted April 29-30, one with 366 current college students and recent graduates and a margin of error of plus or minus 5.2 percentage points and another with 355 parents of students and recent graduates and a margin of error of 5.3 percentage points. The Digital Citizens Alliance is a Washington-based group whose goal is to educate the public and policymakers on threats to consumers on the Internet.
"It’s the rampant abuse that can cause serious health complications and even death," Digital Citizens Alliance executive director Tom Galvin. "Too many young adults are learning a terrible lesson to self-medicate to get through stressful, challenging moments."
Nearly one-quarter of respondents said they or a friend had shared legally prescribed drugs with someone else and perceived the practice as common; 71% of parents regard it as common as well. Fifteen percent of students have ordered drugs online without a prescription or know a friend who has. More than 40% of parents of current or recently graduated students say law enforcement isn’t doing enough to curb the illegal sale of prescription drugs online, compared with more than 17% who say it is.
Patients under doctor’s care more proactive
Not surprising, the majority of respondents who visit the doctor report that they are proactive about their health, according to an online survey of almost 700 AccentHealth viewers conducted in April. And about one-third of respondents indicated that they were "very proactive" about their health.
To see more Patient Views, click here.
Patient Views is a new, exclusive consumer insights feature that appears in every edition of DSN magazine, as well as the daily e-newsletter DSN A.M. If you could ask 6,000 patients anything at all, what would it be? Send your questions to [email protected].
Source: AccentHealth. To view the demographic breakdown of participants, click here.
Teva launches topotecan injection
NORTH WALES, Pa. — Teva Health Systems has launched a generic injectable drug for small-cell lung cancer, the company said Tuesday.
Teva, a subsidiary of Teva Pharmaceuticals, itself a subsidiary of Israel-based Teva Pharmaceutical Industries, announced the launch of topotecan injection in the 1 mg-per-1 mL strength, in 4 mL, single-dose vials.
The drug is a generic version of GlaxoSmithKline’s Hycamtin.
Are you a pharmacy technician working in the retail industry? Find our group on Facebook for more stories like this and join the conversation.